PubMed Health⌕ Search

Biomedical subjects

W Soudijn

Publications and source records attributed to W Soudijn.

At least 55 records · Page 3Linked to original sources

Influence of the molecular structure of N6-(omega-aminoalkyl)adenosines on adenosine receptor affinity and intrinsic activity.

The affinities of a series of N6-(omega-aminoalkyl)adenosines as probes for A1 and A2 adenosine receptors were determined in various radioligand binding assays and the intrinsic activities were measured in adenylate cyclase assays. Clear species differences were noticed for A1 receptor affinity of these adenosine receptor agonists, the compounds being more active in calf than in rat brain tissue. The affinity profile within the series was, however, rather similar in both membrane preparations, with N6-9-aminononyladenosine displaying highest affinity. The A2 receptor affinities were comparable to values measured for the A1 receptor in its low affinity state, as assessed with a radiolabelled antagonist in the presence of 1 mM GTP. Calculation of the intrinsic activities of the adenosine analogues from their modulating action on adenylate cyclase showed almost all the compounds to be equally effective to (-)-N6-(R-phenylisopropyl) adenosine, on either A1 or A2 adenosine receptors. N6-3-Aminopropyl- and N6-12-aminododecyladenosine, however, proved to be partial agonists, the first on A1 and the second on A2 adenosine receptors. The data are used as the basis for a discussion of adenosine receptor subtype selectivity and intrinsic activity in general.

Adenosine↗

Mapping the N6-region of the adenosine A1 receptor with computer graphics.

N6-substituted adenosine derivatives can be very potent and selective agonists at A1 receptors. The N6-region is usually described by a general model introduced by Kusachi et al. (J. Med. Chem. 1985, 28, 1636). Structure-activity relationships for this region have recently been reported from a detailed study by Daly et al. (Biochem. Pharmacol. 1986, 35, 2467). The N6-region of the A1 receptor was now investigated in further detail with the aid of computer graphics. A map of the N6-region was constructed on the basis of a selected set of data from Daly et al. This map allows Kusachi's model to be extended with two new subregions: a C subregion, accommodating cycloalkyl substituents and a B subregion, which is filled by bulky substituents, such as a norbornanyl moiety. Furthermore, three regions can be distinguished, where occupation leads to diminished receptor affinity, so-called forbidden areas. The extended model permits the contribution of each subregion to be determined quantitatively, allowing accurate prediction of affinities of compounds that were not used to construct the map.

Adenosine↗

The antiarrhythmic properties of beta-adrenoceptor antagonists.

The antiarrhythmic properties of beta-adrenoceptor antagonists have long been recognized and, according to the Vaughan Williams classification of antiarrhythmic drugs, these drugs are regarded as a separate entity, namely class II. In this review, Ad IJzerman and Willem Soudijn focus on the nature and the molecular basis of the antiarrhythmic action of beta-adrenoceptor antagonists. Structure-activity relationship studies demonstrate that the antiarrhythmic profile of different beta-adrenoceptor antagonists is not fixed and some compounds have class I or class III properties which may be clinically relevant.

Adrenergic beta-Antagonists↗

Conjunctival keratinisation, an abnormal reaction to an ocular beta-blocker.

Conjunctival leucoplakia was induced by the local beta-blocker metipranolol in one case. Withdrawal of the drug and application of all-trans retinoic acid ointment resulted in resolving of the keratinisation. A striking pharmacological resemblance is discovered between metipranolol and practolol. Metipranolol seems to be a less toxic phenol derivative of practolol. Nevertheless, it seems able to act as antigen.

Chemical Phenomena↗

[3H]batrachotoxinin-A 20-alpha-benzoate binding to sodium channels in rat brain: sensitivity to tetrodotoxin and divalent cations.

The sodium channel blocker tetrodotoxin partially inhibited [3H]batrachotoxinin-A 20-alpha-benzoate binding to rat brain synaptosomes. This inhibition results from a decrease in the apparent affinity of the radioligand, which indicates that sites 1 and 2 of the sodium channel are not independent as thought previously. Computer-assisted data analysis allowed two binding sites for BTX-B to be distinguished. These sites could be differentiated by means of the divalent cations Mg2+ and Ca2+, that inhibit BTX-B binding completely. Tetrodotoxin diminished the inhibition by Mg2+ and vice versa, suggesting a common mechanism of action for the inhibition.

Animals↗

Adenosine derivatives with N6-alkyl, -alkylamine or -alkyladenosine substituents as probes for the A1-receptor.

Three series of N6-substituted adenosine derivatives were synthesized, having in common an unbranched alkyl chain with lengths varying from 2 to 12 methylene units, but differing in their omega-alkyl substituents: N6-n-alkyladenosines (I), N6-omega-amino-alkyladenosines (II) and alpha omega,di-(adenosin-N6-yl)alkanes (III). The compounds of the latter series combine two functional groups in one molecule. A1-receptor affinity of these compounds was measured as inhibition of [3H]PIA binding to calf brain membranes. With relatively short chain lengths, compounds in series I are the most potent. In this series, optimum activity is reached with N6-n-pentyladenosine (Ki = 0.50 nM). With short chain lengths, compounds in series II and III are 6-20-fold less potent than their congeners in series I. The potency order however is reversed with higher chain lengths. While affinity in series II and III increases strongly, reaching an optimum with the nonyl derivatives, affinity in series I decreases sharply with alkyl chains larger than 8 methylene units. Highest affinity is found with 9-amino-nonyladenosine (Ki = 0.32 nM). In general, the omega-aminoalkyl derivatives are somewhat more potent than the corresponding di-adenosinyl derivatives. Implications for the possible topography of the N6 region of the A1-receptor and the area further removed from N6 are discussed.

Adenosine↗

Synthesis of enkephalinase B inhibitors, and their activity on isolated enkephalin-degrading enzymes.

Compounds in which a dipeptide moiety is linked to a metal chelating mercapto group were synthesized to obtain effective enkephalinase B inhibitors. Inhibitors containing two hydrophobic amino acid side-chains decrease enkephalinase B activity with a potency depending on the length of the spacer connecting the mercapto group and the dipeptide (IC50 values vary between 0.35 and 14 microM) and they also inhibit enkephalinase A and aminopeptidase activity. Compounds lacking the carboxy terminal side-chain are not recognized by enkephalinase B or aminopeptidase but are potent inhibitors of enkephalinase A. Our most potent enkephalinase B inhibitor is mercaptoacetyl-Phe-Phe (designated phelorphan), having an IC50 value of 0.35 microM for enkephalinase B. This compound also effectively inhibits enkephalinase A (IC50 = 0.02 microM) and aminopeptidase activity (IC50 = 13 microM). Phelorphan can therefore be considered as a complete inhibitor of enkephalin biodegradation.

Animals↗

Effect of various enkephalin analogs and dipeptides on the enzymatic activity of enkephalinase B isolated from calf-brain striatum.

The inhibitory potency of several enkephalin analogs and dipeptides on the calf-brain enkephalinase B activity was established with the aim to characterize its active site. Highest potency was measured for dipeptides with a large side chain on both amino acids. The nature of the distal amino acid is of minor importance, provided it is not a glycine. Free carboxylic function is required for good interaction, whereas the stereochemical configuration of the dipeptide is less so. Enkephalinase B has only little affinity for D-Ala2-Leu-enkephalin. The data are to be used for the design of new enkephalinase B inhibitors.

Animals↗

Improved qualitative method for establishing flunitrazepam abuse using urine samples and column liquid chromatography with fluorimetric detection.

The abuse of flunitrazepam (Rohypnol), a potent benzodiazepine-type hypnotic, cannot be established with the widely used immunoassays for urine analysis owing to lack of specificity. A simple method is described which is based on the formation of acridine derivatives and measures the sum of metabolites of flunitrazepam in urine samples using column liquid chromatography with fluorimetric detection.

Biotransformation↗

Research in the Division of Medicinal Chemistry.

Within the Center for Bio-Pharmaceutical Sciences research on medicinal chemistry is centered around two themes: receptor recognition and photochemistry of drugs. Extremely little is known about the conformation of receptor recognition sites. The approach that should lead to a more detailed knowledge is outlined. Similarly the interaction between enzymes and their inhibitors will be studied. The photochemistry of drugs can be useful (phototherapy) or harmful (phototoxicity). The phototoxicity of benzodiazepines was found to be attributable to the formation of oxaziridines on the N-oxide groups.

Academies and Institutes↗

Halopemide, a new psychotropic agent. Cerebral distribution and receptor interactions.

Halopemide is a new psychotropic agent, a structural analogue of the neuroleptics of the butyrophenone type but with different pharmacological and clinical properties. Preliminary clinical findings indicate that halopemide lacks the ability to induce parkinsonism and may be an effective drug in the treatment of psychosis characterized by autism, emotional withdrawal or apathy. Its pharmacological effects at a molecular level in comparison to structurally related neuroleptics and putative metabolites are reviewed.

Animals↗

Isolation and characterization of an enkephalin-hydrolyzing dipeptidyl-aminopeptidase from calf-brain striatum.

Cytosolic dipeptidyl-aminopeptidase with a high affinity for Leu-enkephalin (Km = 5-7 microM) was partially purified from the 25,000 g supernatant of calf-brain striatum. The procedure included pH 4.5 denaturation, DEAE-cellulose chromatography and Blue Sepharose CL-6B chromatography and resulted in preparations that are free from other enkephalin-hydrolyzing enzymes. This enzyme, which is called enkephalinase B, has a positively charged group in its active site and presumably also a Zn atom since the loss in activity induced by EDTA treatment can be restored without loss of substrate affinity by low concentrations of ZnSO4.

Animals↗

The combined use of high-performance liquid chromatography and radioimmunoassay for the bioanalysis of nicomorphine and its metabolites.

Methods have been developed for the determination of nicomorphine using reversed-phase HPLC with UV detection; for the simultaneous assay of morphine and mononicotinoylmorphine by a coupled normal-phase HPLC-radioimmunoassay method; and for conjugates of morphine and mononicotinoylmorphine by radioimmunoassay. The methods have been evaluated and applied to a pharmacokinetic study of nicomorphine administered intramuscularly.

Journal Article↗

Computer modelling of the binding of non-selective ligands to biological receptors.

The application of common linearization methods (log-probit analysis or Hill plot transformation) to the evaluation of receptor binding experiments leads to serious errors, if the ligands used possess insufficient receptor selectivity. The use of simultaneous non-linear curve-fitting procedures in this case is recommended and illustrated.

Binding Sites↗

Purification and characterization of enkephalin-degradating enzymes from calf-brain striatum.

Enkephalinase A and B are extracted from Triton-X 100 washed calf-brain particles and purified by DEAE-cellulose chromatography. Both enzymes have identical Km values in their membrane-bound and soluble form. Enkephalinase A has a pH optimum at 6.9 and a Km for Leu-enkephalin of 20-25 microM, which hardly depends on the pH. Thiorphan and phosphate are purely competitive inhibitors of Enkephalinase A with Ki values of 3 nM and 1.5 mM respectively (pH = 6.85). Enkephalinase B is not affected by phosphate or thiorphan. It has a Km for Leu-enkephalin of 10 microM, a pH optimum of 7.0 and is inhibited by low concentrations of apolar dipeptides.

Aminopeptidases↗

Inhibitors of calf-brain enkephalinase A and B.

Enkephalinase A and B isolated from calf-brain striatum have comparable substrate specificity (Km for Leu-enkephalin = 1-3.10(-5) microM) but a quite different affinity for certain inhibitors: phosphate, Secobarbital and Thiorphan are effective inhibitors for Enkephalinase A (IC50 of 2.5 mM, 30 microM and 4 nM respectively), while Enkephalinase B does not react with any of these compounds. Both enzymes are inhibited by 1 mM EDTA and o-phenanthroline indicating the presence of a metal atom in or near their active sites. Although with different abilities, both enzymes recognize dipeptides having at least one hydrophobic amino-acid side chain. The potency of such dipeptides can be used for a description of the active site.

Animals↗

Angiotensin converting enzyme inhibitors.

Inhibition of angiotensin converting enzyme (ACE) in patients suffering from renovascular hypertension results in lowering of the blood-pressure. The development of captopril, an orally active ACE inhibitor and the structure-activity relationship of captopril analogues are described. Some side effects of captopril were attributed to the presence of an SH-group in the molecule. This led to the development of a series of non-mercapto ACE inhibitors derived from captopril. One of them, enalapril, a potent ACE inhibitor with a long duration of antihypertensive action, is now tested in clinical trials.

Angiotensin-Converting Enzyme Inhibitors↗